Immunome (IMNM) director-linked entity awarded 9,897 stock options at $18.16 strike
Rhea-AI Filing Summary
Immunome Inc. director-related entity receives new stock option grant. A director stock option covering 9,897 shares of Immunome common stock was granted at an exercise price of $18.16 per share, expiring on June 9, 2036. The filing lists director Isaac Barchas as reporting person, but he has agreed that any securities granted for his board service are held for the benefit of Arsenal Bridge Ventures, and he disclaims beneficial ownership and all rights in the reported securities.
The option vests in four equal quarterly installments starting on June 10, 2026, through the one-year anniversary, with each vesting date tied to continued service with Immunome. After this award, the reported derivative position in these options is 9,897 units.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Barchas Isaac
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (right to buy) | 9,897 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (right to buy) — 9,897 shares (Direct)
Footnotes (2)
- F1. Mr. Barchas has agreed to receive and hold for the benefit of Arsenal Bridge Ventures any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Barchas disclaims beneficial ownership of, and all right, title and interest in, the reported securities.
- F2. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Barchas' continuous service with the Company on each respective vesting date.
Key Figures
Option grant size: 9,897 options
Exercise price: $18.16 per share
Expiration date: June 9, 2036
+2 more
5 metrics
Option grant size
9,897 options
Director stock option covering common stock
Exercise price
$18.16 per share
Strike price of director stock option
Expiration date
June 9, 2036
Option term end date
Post-transaction derivative holdings
9,897 options
Total options held in this award after grant
Vesting schedule
4 equal quarterly installments
From June 10, 2026 over one year, service-based
Key Terms
Director Stock Option (right to buy), beneficial ownership, vests in four equal quarterly installments, exercise price, +1 more
5 terms
Director Stock Option (right to buy) financial
"security_title: "Director Stock Option (right to buy)""
beneficial ownership financial
"Mr. Barchas disclaims beneficial ownership of the reported securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
vests in four equal quarterly installments financial
"The option vests in four equal quarterly installments, commencing from June 10, 2026"
exercise price financial
"conversion_or_exercise_price: "18.1600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-09T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Immunome (IMNM) report for Isaac Barchas?
Immunome reported a grant of 9,897 director stock options linked to Isaac Barchas’ board service. The options allow purchase of common stock at $18.16 per share and are structured as compensation, not an open‑market trade.
Who ultimately benefits from the new Immunome (IMNM) stock options?
According to the disclosure, Isaac Barchas has agreed that securities granted for his director service are held for the benefit of Arsenal Bridge Ventures. He disclaims beneficial ownership and all right, title, and interest in the reported option award.
What is the exercise price and expiration of the Immunome (IMNM) option grant?
The option has an exercise price of $18.16 per share and expires on June 9, 2036. This means the holder can choose to buy Immunome common shares at that fixed price any time before the expiration date, subject to vesting.
How does the Immunome (IMNM) director stock option vest over time?
The option vests in four equal quarterly installments starting on June 10, 2026. Vesting continues each succeeding fiscal quarter for one year, and each installment requires Isaac Barchas’ continuous service with Immunome on the applicable vesting date.